Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
BioRap Technologies, Ltd.
Agreement signed with HaptoGuard for diabetes therapies
June 22nd, 2005
BioRap Technologies, Ltd., a private company that manages the commercialization of intellectual property developed by members of the Rappaport Family Institute for Research in the Medical Sciences at the Technion, announced that it has expanded its license and research agreement with HaptoGuard, Inc., an American biopharmaceutical company focused on the development and commercialization of anti-inflammatory therapeutics for large, underserved populations. The agreement will allow HaptoGuard to further develop diagnostic and therapeutic products for the management and treatment of diabetes-related complications. "This agreement extends the scope of...
Source: Physician Law Weekly (2005-06-22)
|
